© accelopment Schweiz AG · [email protected] · ISO 9001 certified · Read our Privacy Policy
The two updated COVend posters explain the technology behind the project in detail and offer an in-depth look at the innovative IXION 2.0 clinical trial, as well as general key facts about the project and its latest accomplishments.
The poster presenting the research findings of the COVend consortium partner, Systems Biology Ireland (UCD), on Fibrin-derived Peptide FX06 Protecting Human Pulmonary Endothelial Cells Against COVID-19-Triggered Cytokines.
The COVend press release available in English and German announces the start of patient enrollment for the IXION 2.0 clinical trial and project's shift to investigating the potential benefits of the FX06 drug for patients with ARDS.
The two COVend posters explain the technology behind the project in detail and are mainly targeted at a medical and scientific audience but also serve as a project overview for a non-expert audience.
A poster prepared by Zhiran Wang and the UCD & SBI team presents their findings on mimicking the inflammatory response of COVID-19 in endothelial cells and FX06 reducing the harmful effects of the cytokines on the cells.
A poster prepared by Clazinus Veijer highlights the results from a systematic review on various methodological characteristics of model-based economic evaluations of COVID-19 treatments conducted by the UMCG team.
This COVend roll-up contains all key facts about the project, including links to the project's communication channels.
This project factsheet informs about the background, objectives, main concept of the project. Available in English and German.
The first COVend press release presents the background and objectives of the project and announces it to a broad audience.
Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.
FOR INQUIRIES, PLEASE SEND US AN EMAIL AT [email protected]
© accelopment Schweiz AG · [email protected] · ISO 9001 certified · Read our Privacy Policy